弥漫性中线胶质瘤的自适应免疫治疗范式:整合表观遗传重编程、神经元-胶质瘤相互作用与肿瘤微环境调控
本综述评估了弥漫性中线胶质瘤(DMG,含DIPG)现有免疫治疗的应用,涵盖抗H3K27M肽疫苗、CAR-T、免疫检查点调控和放射免疫治疗等临床前及早期临床研究,并纳入癌症神经科学中神经元-肿瘤相互作用与免疫抑制微环境的相关进展,指出免疫治疗正从概念走向转化现实。
要点
- DMG可由组蛋白H3 K27M突变稳定识别,该突变与侵袭性生物学、治疗抵抗和极差生存相关。
- 新抗原靶向疫苗与针对表面抗原的CAR-T细胞疗法显示出有希望的早期疗效。
- 神经元-胶质瘤突触与旁分泌信号可能介导肿瘤进展和免疫逃逸。
核心结论
- DMG的免疫治疗正从概念状态向转化现实推进。
- 深入理解肿瘤-免疫-神经交互、联合治疗及儿童患者免疫生物学,对克服耐药和实现持久控制至关重要。
研究设计与样本
- 综述类研究,检索并评估DMG免疫治疗的临床前与早期临床研究。
- 纳入的免疫治疗模式包括抗H3K27M抗原肽疫苗、嵌合抗原受体T细胞疗法、免疫检查点调控和放射免疫治疗。
- 整合癌症神经科学中肿瘤与神经元相互作用及DMG微环境免疫抑制的相关进展。
主要发现
- DMG因低肿瘤突变负荷、免疫豁免部位和强抑制性肿瘤微环境而传统上免疫反应性差。
- 多种不同免疫治疗策略已显示出有希望的早期疗效。
- 新抗原靶向疫苗和使用表面抗原的CAR-T细胞疗法尤受关注。
- 初步发现提示神经元-胶质瘤突触和旁分泌信号在介导肿瘤进展与免疫逃逸中起重要作用。
临床怎么用
- 关注新抗原靶向疫苗和表面抗原CAR-T等免疫治疗在DMG中的早期研究证据。
- 在免疫治疗设计中考虑神经元-肿瘤交互及肿瘤微环境免疫抑制的影响。
- 联合治疗和儿童免疫生物学理解是应对耐药、争取持久控制的关键方向。
局限性
- 综述基于临床前和早期临床研究,尚缺乏成熟疗效数据。
- DMG的低突变负荷、免疫豁免部位和抑制性微环境构成疗效障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse midline gliomas, including diffuse intrinsic pontine gliomas, represent one of the most aggressive pediatric malignancies in the central nervous system with a uniformly poor prognosis. They can be consistently identified by mutations in histone H3 K27M, which are associated with aggressive tumor biology, marked resistance to therapies, and abysmal survival. The current review critically assesses the existing application of immunotherapeutic modalities in DMGs, emphasizing biological hurdles in efficacy, translation methodologies, and prospects in attaining sustained responses. METHODS: We examined preclinical and early clinical studies in DMGs for immune therapies such as peptide vaccines against H3K27M antigens, chimeric antigen receptor T-cell therapies, immune checkpoint modulation, and radioimmunotherapy. Current developments in the interface of cancer neuroscience and tumor interaction with neurons were incorporated in a manner relevant to immune suppression in the microenvironment of DMG. Although these tumors have traditionally shown poor immune reactivity because of low tumor mutational burden, immune-privileged sites, and a strongly suppressive tumor microenvironment, a variety of different immune therapeutic approaches have shown promising early efficacy. Of particular interest are neoantigen-targeted vaccines and CAR T-cell therapy using surface antigens. Preliminary findings suggest an important role for neuron-glioma synaptic and paracrine signaling in mediating tumor progression and immune evasion. CONCLUSIONS: Immunotherapy for DMGs is moving from a conceptual state to a translational reality. A better understanding of the realm of tumor immune-neural crosstalk, combination therapies, and immune biology in pediatric patients will be critical in addressing resistance and providing durable control for these aggressive malignancies.
引用
- Liu J, Ha JH, Abikenari M, et al. Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation. J Neurooncol. 2025. PMID: 41460355. doi:10.1007/s11060-025-05347-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。